BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei Y, Xiao X, Lao XM, Zheng L, Kuang DM. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cell Mol Life Sci 2021;78:867-87. [PMID: 32940722 DOI: 10.1007/s00018-020-03637-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liang B, Hu X, Ding Y, Liu M. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. J Cell Physiol 2021;236:4138-51. [PMID: 33275291 DOI: 10.1002/jcp.30197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shen Y, Zhang B, Wei X, Guan X, Zhang W. CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration. Int Immunopharmacol 2021;103:108454. [PMID: 34929481 DOI: 10.1016/j.intimp.2021.108454] [Reference Citation Analysis]
3 Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, Lotfinejad P. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. J Cell Physiol 2021. [PMID: 34825383 DOI: 10.1002/jcp.30645] [Reference Citation Analysis]